The company should have remained in suspension and released the results, organised the conference call to answer any questions or ambiguities (if they exist) and then come out of suspension. This would have been especially relevant last year. The panic selling, is often indicative of not being comfortable with the information at hand or clarity over the information that has been made available.
I think the volume (a fraction of what was sold last time), seems to indicate that there is a sense of a macro thought process here, many milestones have been met since last year, especially OSA, the Australian studies and for what it's worth $10M + in the bank.
The results have indicated that the application works and there is an opportunity to apply to the FDA for a number of the conditions (see announcement). There seems to be more information to come, also, the Australian studies being submitted to a peer-reviewed medical journal, will add clout to CE and TGA approval.
This is positive, but the process of these trials is complicated, especially when there is such a discrepancy in the adjudication of the results, the experienced human diagnosis couldn't determine whether the result was one or the other in over 30% of the cases. That's a significant figure and in a strange way, speaks more to the need of a robust, innovative, technological intervention that is affordable reliable and mitigates human subjectivity (the very essence of the company).
Patience is necessary with every investment.
